OptimizeRx Corp Files 2023 Annual Report on Form 10-K

TL;DR

<b>OptimizeRx Corporation filed its 2023 10-K report, detailing its financial performance and corporate status.</b>

AI Summary

OptimizeRx Corp (OPRX) filed a Annual Report (10-K) with the SEC on April 15, 2024. OptimizeRx Corporation filed its annual report for the fiscal year ended December 31, 2023. The company is incorporated in Nevada and its principal executive offices are located in Waltham, MA. OptimizeRx Corporation's common stock is traded on the NASDAQ Capital Market under the ticker symbol OPRX. The filing indicates that OptimizeRx Corporation is a non-accelerated filer and a smaller reporting company. The company has submitted all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking OptimizeRx Corp, this filing contains several important signals. This 10-K filing provides a comprehensive overview of OptimizeRx's financial health and operational status for the fiscal year 2023, crucial for investors to assess performance and future outlook. As a publicly traded company on NASDAQ, OptimizeRx's adherence to SEC filing requirements, including this 10-K, is essential for maintaining transparency and investor confidence.

Risk Assessment

Risk Level: low — OptimizeRx Corp shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate negative news or significant changes, indicating a routine disclosure.

Analyst Insight

Monitor future filings for detailed financial results and strategic updates from OptimizeRx Corp.

Key Numbers

• 2023-12-31 — Fiscal Year End (The report covers the fiscal year ended on this date.)
• 2024-04-15 — Filing Date (The date the 10-K was filed with the SEC.)
• 001-38543 — Commission File Number (SEC identifier for the company.)
• 26-1265381 — IRS Number (Internal Revenue Service employer identification number.)

Key Players & Entities

• OptimizeRx Corp (company) — Filer name
• 2023-12-31 (date) — Fiscal year end
• 2024-04-15 (date) — Filing date
• Nevada (jurisdiction) — State of incorporation
• Waltham, MA (location) — Principal executive offices
• OPRX (ticker) — Trading Symbol
• NASDAQ Capital Market (exchange) — Name of exchange

FAQ

Industry Context

OptimizeRx operates in the business services sector, providing technology solutions within the healthcare industry.

Regulatory Implications

The company is subject to standard SEC reporting requirements for publicly traded entities.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management's discussion and analysis.
2. Analyze OptimizeRx's competitive positioning and growth strategies outlined in the report.
3. Track future SEC filings for updates on financial performance and corporate developments.

Year-Over-Year Comparison

This is the initial 10-K filing analyzed, so no prior filing data is available for comparison.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 OPRX NASDAQ Capital Market Securities
• $30 billion — d in the United States of approximately $30 billion. We believe significant opportunity e
• $71.5 million — ighlights 1. Net revenue increased to $71.5 million in 2023, a 15% increase over 2022. 2.

Filing Documents

• ea0203848-10k_optimizerx.htm (10-K) — 1437KB
• ea020384801ex10-26_optimize.htm (EX-10.26) — 23KB
• ea020384801ex10-27_optimize.htm (EX-10.27) — 23KB
• ea020384801ex10-28_optimize.htm (EX-10.28) — 147KB
• ea020384801ex19-1_optimize.htm (EX-19.1) — 79KB
• ea020384801ex21-1_optimize.htm (EX-21.1) — 3KB
• ea020384801ex23-1_optimize.htm (EX-23.1) — 4KB
• ea020384801ex31-1_optimize.htm (EX-31.1) — 11KB
• ea020384801ex31-2_optimize.htm (EX-31.2) — 11KB
• ea020384801ex32-1_optimize.htm (EX-32.1) — 7KB
• ea020384801ex97-1_optimize.htm (EX-97.1) — 27KB
• image_001.jpg (GRAPHIC) — 5KB
• ex23-1_001.jpg (GRAPHIC) — 15KB
• ex10-26_001.jpg (GRAPHIC) — 4KB
• ex10-27_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-033000.txt (&nbsp;) — 8345KB
• oprx-20231231.xsd (EX-101.SCH) — 80KB
• oprx-20231231_cal.xml (EX-101.CAL) — 57KB
• oprx-20231231_def.xml (EX-101.DEF) — 364KB
• oprx-20231231_lab.xml (EX-101.LAB) — 685KB
• oprx-20231231_pre.xml (EX-101.PRE) — 369KB
• ea0203848-10k_optimizerx_htm.xml (XML) — 1036KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 5 Item 1B. Unresolved Staff Comments 17 Item 1C. Cybersecurity 17 Item 2.

Properties

Properties 19 Item 3.

Legal Proceedings

Legal Proceedings 19 Item 4. Mine Safety Disclosures 19 Item 4.1 Information about Our Executive Officers 20 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 22 Item 6. Reserved 22 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 31 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 32 Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure 33 Item 9A.

Controls and Procedures

Controls and Procedures 33 Item 9B. Other Information 34 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 35 PART III Item 10. Directors, Executive Officers and Corporate Governance 36 Item 11.

Executive Compensation

Executive Compensation 36 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 36 Item 13. Certain Relationships and Related Transactions, and Director Independence 37 Item 14. Principal Accountant Fees and Services 37 PART IV Item 15. Exhibits and Financial Statement Schedules 38 Item 16. Form 10-K Summary 38 i PART I Forward-Looking This Annual Report on Form 10-K contains statements that relate to future events and expectations and, as such, constitute forward-looking information, including estimates, projections, statements relating to our strategies, outlook, business and financial prospects, business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Forward-looking statements are not guarantees of future performance. Although OptimizeRx believes that the expectations reflected in any forward-looking statements are based on reasonable assumptions, these expectations may not be attained and it is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of risks, uncertainties and changes in circumstances, many of which are beyond OptimizeRx's control. For a discussion of some of the specific factors that could cause actual results to differ materially

View Full Filing

View this 10-K filing on SEC EDGAR